Cellectis SA (CLLS)
1.87
+0.01
(+0.54%)
USD |
NASDAQ |
Nov 22, 16:00
1.88
+0.01
(+0.53%)
After-Hours: 20:00
Cellectis Cash from Financing (Quarterly): -4.218M for Sept. 30, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | -4.218M |
| June 30, 2024 | 78.51M |
| March 31, 2024 | 11.90M |
| December 31, 2023 | 41.58M |
| September 30, 2023 | 1.688M |
| June 30, 2023 | 19.82M |
| March 31, 2023 | 19.78M |
| December 31, 2022 | -5.042M |
| September 30, 2022 | -4.12M |
| June 30, 2022 | 2.63M |
| March 31, 2022 | 7.677M |
| December 31, 2021 | -1.423M |
| September 30, 2021 | -3.682M |
| June 30, 2021 | 42.84M |
| March 31, 2021 | 9.79M |
| December 31, 2020 | 12.68M |
| September 30, 2020 | 16.54M |
| June 30, 2020 | 0.001M |
| March 31, 2020 | -1.899M |
| December 31, 2019 | -1.025M |
| Date | Value |
|---|---|
| September 30, 2019 | -0.838M |
| June 30, 2019 | -0.721M |
| March 31, 2019 | -1.278M |
| December 31, 2018 | 0.164M |
| September 30, 2018 | 1.913M |
| June 30, 2018 | 230.93M |
| March 31, 2018 | 3.485M |
| December 31, 2017 | 0.953M |
| September 30, 2017 | 39.18M |
| June 30, 2017 | 0.849M |
| March 31, 2017 | 0.282M |
| December 31, 2016 | 0.055M |
| September 30, 2016 | 0.1497M |
| June 30, 2016 | -0.011M |
| March 31, 2016 | 0.2913M |
| December 31, 2015 | 0.433M |
| September 30, 2015 | 1.057M |
| June 30, 2015 | 218.77M |
| March 31, 2015 | 0.327M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-5.042M
Minimum
Dec 2022
78.51M
Maximum
Jun 2024
12.20M
Average
5.154M
Median
Cash from Financing (Quarterly) Benchmarks
| Edap TMS SA | 0.6422M |
| Genfit SA | -- |
| DBV Technologies SA | 0.007M |
| Akari Therapeutics PLC | -0.443M |
| Biodexa Pharmaceuticals PLC | -- |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -5.829M |
| Cash from Investing (Quarterly) | 22.33M |
| Free Cash Flow | 60.38M |
| Free Cash Flow Per Share (Quarterly) | -0.0663 |
| Free Cash Flow to Equity (Quarterly) | -8.455M |
| Free Cash Flow to Firm (Quarterly) | -6.634M |
| Free Cash Flow Yield | 36.04% |